Ubiquitin ligase KPC1 promotes processing of P105 NF-κB1 to p50, eliciting strong tumor suppression
AssigneeTechnion Research & Development Foundation Limited
InventorsAaron Ciechanover, Yelena Kravtsova, Inna Shomer, Victoria Cohen
Life of this patent
Estimating the term…
Abstract
The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.
Claims7
A method of treating cancer in a subject comprising the step of administering to said subject a therapeutically effective amount of:
- (b) an expression vector comprising a nucleic acid that encodes a fused protein comprising the KPC1 sequence as set forth in SEQ ID NO:
- 4,
- wherein said method comprises administering the expression vector as described in (b).
A method of treating cancer in a subject comprising the step of administering to said subject a therapeutically effective amount of:
- (b) an expression vector comprising a nucleic acid that encodes a fused protein comprising the KPC1 sequence as set forth in SEQ ID NO:
- 4,
- wherein said fused protein comprises an immunoglobulin, an antibody, an albumin, an albumin-binding moiety, or a combination thereof.
Dependencies are inferred from the claim text.